Department of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA; Novo Nordisk Foundation Center for Biosustainability at the School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Department of Chemical and Biomolecular Engineering, National University of Singapore, 4 Engineering Drive 4, Singapore 117585, Singapore; Bioprocessing Technology Institute, Agency for Science, Technology and Research (A(∗)STAR), 20 Biopolis Way, 06-01, Centros, Singapore 138668, Singapore.
Cell Syst. 2016 Nov 23;3(5):434-443.e8. doi: 10.1016/j.cels.2016.10.020.
Chinese hamster ovary (CHO) cells dominate biotherapeutic protein production and are widely used in mammalian cell line engineering research. To elucidate metabolic bottlenecks in protein production and to guide cell engineering and bioprocess optimization, we reconstructed the metabolic pathways in CHO and associated them with >1,700 genes in the Cricetulus griseus genome. The genome-scale metabolic model based on this reconstruction, iCHO1766, and cell-line-specific models for CHO-K1, CHO-S, and CHO-DG44 cells provide the biochemical basis of growth and recombinant protein production. The models accurately predict growth phenotypes and known auxotrophies in CHO cells. With the models, we quantify the protein synthesis capacity of CHO cells and demonstrate that common bioprocess treatments, such as histone deacetylase inhibitors, inefficiently increase product yield. However, our simulations show that the metabolic resources in CHO are more than three times more efficiently utilized for growth or recombinant protein synthesis following targeted efforts to engineer the CHO secretory pathway. This model will further accelerate CHO cell engineering and help optimize bioprocesses.
中国仓鼠卵巢(CHO)细胞在生物治疗蛋白生产中占据主导地位,广泛应用于哺乳动物细胞系工程研究。为了阐明蛋白生产中的代谢瓶颈,并指导细胞工程和生物工艺优化,我们重建了 CHO 中的代谢途径,并将其与仓鼠基因组中的>1700 个基因相关联。基于该重建的基因组规模代谢模型 iCHO1766 以及 CHO-K1、CHO-S 和 CHO-DG44 细胞的细胞系特异性模型,为生长和重组蛋白生产提供了生化基础。这些模型准确预测了 CHO 细胞的生长表型和已知的营养缺陷型。利用这些模型,我们量化了 CHO 细胞的蛋白合成能力,并证明了常见的生物工艺处理,如组蛋白去乙酰化酶抑制剂,不能有效地提高产物产量。然而,我们的模拟表明,在针对 CHO 分泌途径进行工程改造后,CHO 中的代谢资源在用于生长或重组蛋白合成时的利用率提高了三倍以上。该模型将进一步加速 CHO 细胞工程,并有助于优化生物工艺。